Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials
The effect of COVID and metabolic disease and early treatment
Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) joins Prof Hertzel Gerstein (McMaster University, Hamilton, ON, CA) to discuss the current landscape of cardiometabolic therapies for COVID-19.
Dr Kosiborod talks about the cardiometabolic risk factors for death in people who are hospitalised with COVID-19.
Recorded remotely from Hamilton and Kansas City, 2020.
This discussion was supported by an unrestricted educational grant from Novo Nordisk.
Recorded remotely from Hamilton and Kansas City, 2020.
This discussion was supported by an unrestricted educational grant from Novo Nordisk.
Programme Outline
This discussion was supported by an unrestricted educational grant from Novo Nordisk.